Ainos, Inc.
AIMDHealthcare|Biotechnology|US
$0.70
+0.07 (+11.13%)
Cash / Share
$0.19
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT00690885 Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis | Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis | P2 | Terminated | 1 | RCT, Double-blind | interferon-alpha lozenges, placebo lozenges |
| NCT00895947 Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu | Upper Respiratory Tract Infections | P2 | Completed | 200 | RCT, Double-blind | interferon-alpha |
| NCT00454181 Treatment of Oral Warts in HIV+ Patients | Papillomatosis, HIV Infections | P2 | Completed | 59 | RCT, Double-blind | Interferon-alpha |
| NCT01146535 Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment | Influenza A Virus Infection | P2 | Completed | 40 | RCT, Double-blind | Interferon-alpha, Oseltamivir |
| NCT00483184 Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease | Behcet Syndrome, Behcet Disease | P2 | Completed | 84 | RCT, Double-blind | Veldona, |
| NCT01442779 Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | Respiratory Tract Diseases, Lung Diseases | P2 | Completed | 18 | Open-label | Interferon alpha oral lozenge |
| NCT00695019 Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C | Hepatitis C, Chronic | P2 | Completed | 169 | RCT, Double-blind | interferon-alpha lozenges, placebo lozenges |
| NCT05557318 Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge | Vaginal Infection, Vaginitis | N/A | Unknown | 120 | Open-label | — |